×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
NASDAQ:BCEL

Atreca Stock Forecast, Price & News

$2.23
+0.44 (+24.58%)
(As of 07/5/2022 05:45 PM ET)
Add
Compare
Today's Range
$1.72
$2.27
50-Day Range
$1.56
$2.21
52-Week Range
$1.51
$9.77
Volume
609,563 shs
Average Volume
1.11 million shs
Market Capitalization
$84.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Atreca MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
591.2% Upside
$15.00 Price Target
Short Interest
Bearish
14.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.31mentions of Atreca in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$30,300 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.74) to ($2.49) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.34 out of 5 stars

Medical Sector

177th out of 1,428 stocks

Pharmaceutical Preparations Industry

74th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive BCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter.

Atreca logo

About Atreca (NASDAQ:BCEL) Stock

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

BCEL Stock News Headlines

Atreca to Present at Upcoming Investor Conferences
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCEL
Fax
N/A
Employees
134
Year Founded
N/A

Company Calendar

Last Earnings
5/11/2022
Today
7/05/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+572.6%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-109,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.10 per share

Miscellaneous

Free Float
34,134,000
Market Cap
$84.20 million
Optionable
Not Optionable
Beta
0.64














Atreca Frequently Asked Questions

Should I buy or sell Atreca stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Atreca stock.
View analyst ratings for Atreca
or view top-rated stocks.

What is Atreca's stock price forecast for 2022?

4 brokerages have issued 1-year target prices for Atreca's shares. Their BCEL stock forecasts range from $9.00 to $25.00. On average, they expect Atreca's share price to reach $15.00 in the next year. This suggests a possible upside of 572.6% from the stock's current price.
View analysts' price targets for Atreca
or view top-rated stocks among Wall Street analysts.

How has Atreca's stock performed in 2022?

Atreca's stock was trading at $3.03 at the start of the year. Since then, BCEL stock has decreased by 26.4% and is now trading at $2.23.
View the best growth stocks for 2022 here
.

When is Atreca's next earnings date?

Atreca is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Atreca
.

How were Atreca's earnings last quarter?

Atreca, Inc. (NASDAQ:BCEL) posted its earnings results on Wednesday, May, 11th. The company reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.13.
View Atreca's earnings history
.

Who are Atreca's key executives?

Atreca's management team includes the following people:
  • Mr. John A. Orwin, Pres, CEO & Director (Age 57, Pay $889.51k)
  • Dr. Tito A. Serafini Ph.D., Founder, Chief Strategy Officer & Director (Age 59, Pay $662.77k)
  • Mr. Herbert C. Cross, Chief Financial Officer (Age 50, Pay $589.23k)
  • Dr. Yann Chong Tan, Chief Technologist
  • Ms. Courtney J. Phillips J.D., Gen. Counsel & Corp. Sec. (Age 47)
  • Dr. Daniel Emerling, Sr. VP of Research
  • Dr. Jonathan Benjamin M.D., Ph.D., Sr. VP of Clinical Research

What is John Orwin's approval rating as Atreca's CEO?

2 employees have rated Atreca CEO John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among Atreca's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Atreca own?

When did Atreca IPO?

(BCEL) raised $126 million in an initial public offering on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

What is Atreca's stock symbol?

Atreca trades on the NASDAQ under the ticker symbol "BCEL."

How do I buy shares of Atreca?

Shares of BCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atreca's stock price today?

One share of BCEL stock can currently be purchased for approximately $2.23.

How much money does Atreca make?

Atreca (NASDAQ:BCEL) has a market capitalization of $84.20 million. The company earns $-109,320,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis.

How many employees does Atreca have?

Atreca employs 134 workers across the globe.

How can I contact Atreca?

Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The official website for Atreca is www.atreca.com. The company can be reached via phone at (650) 595-2595 or via email at ir@atreca.com.

This page (NASDAQ:BCEL) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.